Source link : https://newshealth.biz/health-news/first-in-class-kras-degrader-promising-in-pancreatic-lung-cancers/
While a number of therapies are approved for use against KRAS G12C mutations, including non-small cell lung cancer, no targeted therapies directed against KRAS G12D have FDA approval. In a phase I trial, setidegrasib showed efficacy in patients with previously treated advanced KRAS G12D-mutated pancreatic ductal adenocarcinoma or non-small cell lung cancer. The treatment was […]
The post First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-25 21:34:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8